[Cell therapy for Parkinson's disease with induced pluripotent stem cells].
Animals
Autografts
Carcinogenesis
Cell- and Tissue-Based Therapy
/ adverse effects
Dopaminergic Neurons
Dyskinesias
/ etiology
Embryonic Stem Cells
HLA Antigens
Histocompatibility
Humans
Immune Tolerance
Induced Pluripotent Stem Cells
/ pathology
Parkinson Disease
/ therapy
Risk
Stem Cell Transplantation
/ adverse effects
Parkinson
cell therapy
clinical trial
induced pluripotent stem cell
Journal
Rinsho shinkeigaku = Clinical neurology
ISSN: 1882-0654
Titre abrégé: Rinsho Shinkeigaku
Pays: Japan
ID NLM: 0417466
Informations de publication
Date de publication:
28 Mar 2019
28 Mar 2019
Historique:
pubmed:
1
3
2019
medline:
25
4
2019
entrez:
1
3
2019
Statut:
ppublish
Résumé
Cell therapy for Parkinson's disease has a history of being applied clinically with aborted embryos as donor source. Efficacy of the therapy under the appropriate condition has been reported. Based on this experience and the advancement of stem cell technology, clinical trials of cell therapy with embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) are going to start soon in several countries. In Japan a physician-initiated clinical trial of iPSC-based therapy for Parkinson's disease has launched since 2018. This trial adopts allogeneic transplantation with a cell line from iPSC stock. This article discusses patient selection, procedure, and risk of the therapy. It also introduces the world's current situation of the cell therapy for Parkinson's disease.
Identifiants
pubmed: 30814448
doi: 10.5692/clinicalneurol.cn-001235
doi:
Substances chimiques
HLA Antigens
0
Types de publication
Journal Article
Review
Langues
jpn
Sous-ensembles de citation
IM